Comment on

• Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study.

  Wagener DJ, Verdonk HE, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Mathieu-Boué A, Verweij J. Wagener DJ, et al. Ann Oncol. 1995 Feb;6(2):129-32. doi: 10.1093/oxfordjournals.annonc.a059107. Ann Oncol. 1995. PMID: 7786820 Clinical Trial.
• Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

  Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M. Catimel G, et al. Ann Oncol. 1995 Feb;6(2):133-40. doi: 10.1093/oxfordjournals.annonc.a059108. Ann Oncol. 1995. PMID: 7786821 Clinical Trial.